FDA Approves Teverelix Phase 2b Study for High-Risk Cancer
In prior testing, teverelix achieved rapid testosterone suppression with a 97.5% probability of castration shortly after dosing in a...
Jon Napitupulu
Clearmind Trial Reinforces Favorable CMND-100 Safety Profile
Clearmind reported no serious adverse events and continued good tolerability in six additional patients completing treatment in the second...
Argá Medtech PFA Shows 94% Durability in Burst-AF Trial
BURST-AF, a 101-patient first-in-human study of Argá Medtech’s Coherent Sine-Burst Electroporation platform, reported 100% procedural success and 94% overall...
First Youth Enrolled in Promising Pediatric T1D Afrezza Study
MannKind has enrolled the first patient in INHALE-1ST, a U.S. multi-center, single-arm study evaluating Afrezza (inhaled human insulin) initiated...
Innocare IND Approval For New VAV1 Degrader Trial In China
InnoCare Pharma has received CDE approval from China’s NMPA to begin clinical trials of ICP-538, an oral VAV1-directed molecular...
MAPS, Columbia U Partner on First MDMA Couples Therapy Study
Enrollment targets are modest but specific: 50–100 anonymous survey responses and 10–20 confidential interviews, backed by Columbia University IRB...
Halneuron® Phase 2b Trial Reaches 50% Enrollment Milestone
Interim data from Dogwood Therapeutics’ ongoing Phase 2b HALT-CINP study point to a favorable operational and clinical signal: a...
Pulmovant Completes Enrollment for Phase 2 PH-ILD Study
In early clinical testing, a single inhaled dose of mosliciguat reduced pulmonary vascular resistance by up to 38% and...
Onward Study Offers Hope for SCI Blood Pressure Control
Feasibility data published in 2025 reported immediate, sustained increases in blood pressure with implant-based spinal cord stimulation in people...
New Trial Data: Comparable Survival Despite Genetic Mismatch
One-year overall survival exceeded 80% across all mismatch levels in the prospective, 268-patient ACCESS trial of mismatched unrelated donor...